CD39/ecto-adpase for treatment of thrombotic and ischemic disorders

Abstract

The present invention relates to a method for treating an ischemic disorder in a subject which comprises administering to the subject a CD39 polypeptide (SEQ ID NO:2) or an active fragment thereof which inhibits ADP or ATP mediated platelet aggregation or leukocyte accumulation so as to treat the ischemic disorder in the subject.

1 - 26 . (canceled)  
     
     
         27 . A method for treating an ischemic disorder in a subject which comprises administering to the subject a CD39 polypeptide (SEQ ID NO:2) or an active fragment thereof which inhibits ADP or ATP mediated platelet aggregation or leukocyte accumulation so as to treat the ischemic disorder in the subject.  
     
     
         28 . The method of  claim 27 , wherein the leukocyte is a white blood cell, a neutrophil, a monocyte or a platelet.  
     
     
         29 . The method of  claim 27 , wherein the subject is a mammal.  
     
     
         30 . The method of  claim 27 , wherein the mammal is a human.  
     
     
         31 . The method of  claim 29 , wherein the ischemic disorder comprises a peripheral vascular disorder, a pulmonary embolus, a venous thrombosis, a myocardial, infarction, a transient ischemic attack, unstable angina, a reversible ischemic neurological deficit, sickle cell anemia or a stroke disorder.  
     
     
         32 . The method of  claim 27 , wherein the subject is undergoing heart surgery, lung surgery, spinal surgery, brain surgery, vascular surgery, abdominal surgery, or organ transplantation surgery.  
     
     
         33 . The method of  claim 32 , wherein the organ transplantation surgery comprises heart, lung, pancreas or liver transplantation surgery.